TB-500: what the peptide is and what research actually shows

Last updated 2026-07-25

What is TB-500?

TB-500 is the name given to a synthetic peptide derived from thymosin beta-4 (TB4), a naturally occurring protein found in nearly every human and animal cell. The name is a trademark from Ceregen (formerly RegenRx) for a specific formulation, but online it gets used loosely to mean any synthetic version of the active fragment of TB4, usually the acetylated 17-23 sequence (Ac-LKKTETQ). That's an important distinction. TB-500 is not thymosin beta-4 itself. It's built around a small fragment of the full 43-amino-acid protein, chosen because early researchers believed it carried much of TB4's actin-binding and cell-migration activity. A 2012 analytical chemistry paper focused specifically on synthesizing and characterizing this N-terminal acetylated 17-23 fragment identified in TB-500 material, precisely because regulators needed a reliable way to confirm what was actually in circulating product ^[1]. So when someone asks "what is TB500 peptide," the honest answer has two parts: it's a lab-made peptide related to a real, well-studied endogenous protein, and it's also a loosely-used commercial name that doesn't always refer to a single, consistent molecule. That matters for anyone trying to compare studies or dosing claims, because "TB-500" in one paper may not be identical to "TB-500" in a vendor's marketing copy.

How is TB-500 different from thymosin beta-4?

Thymosin beta-4 is the full-length, naturally occurring 43-amino-acid protein. TB-500 is a synthetic peptide built around a short fragment of it. They are related, not interchangeable, and a lot of sloppy sourcing online treats them as the same thing. Full-length TB4 has documented roles in actin regulation, cell migration, and tissue repair signaling, which is why it drew research interest in wound healing and cardiac tissue models in the first place. TB-500, as a fragment-based synthetic analog, was developed on the theory that it would produce similar biological effects with better stability and diffusion characteristics than the full protein. Whether it actually reproduces the full spectrum of native TB4 activity in humans is not settled science; most of the direct evidence is in vitro or in animal models, not human trials. A 2024 study using UHPLC-Q-Exactive Orbitrap mass spectrometry quantified TB-500 and its metabolites in vitro and in rats, and screened the compound and its breakdown products for wound-healing activity in cell culture ^[2]. That's a real, useful piece of evidence. It's also, by its own design, preclinical: rats and cell dishes, not people. If you want to go deeper on how the fragment compares to the parent molecule, see tb4 peptide vs tb500.

What does the research actually show TB-500 does?

The current published record on TB-500 is dominated by analytical chemistry and doping-detection papers, plus a small number of mechanism and safety reviews. There is no large human clinical trial establishing efficacy for injury repair in people. A 2026 orthopaedic review in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews covers therapeutic peptides in orthopaedics broadly, discussing applications, challenges, and future directions for the category that includes TB-500-type products ^[3]. A companion 2026 paper in The American Journal of Sports Medicine, framed as a primer for orthopaedic and sports medicine physicians on injectable peptide therapy, walks through what clinicians are actually being asked about by patients and athletes ^[4]. A third 2026 review in Sports Medicine (Auckland) looks specifically at safety and efficacy data, comparing approved versus unapproved peptide therapies used for musculoskeletal injuries and athletic performance ^[5]. The pattern across these reviews is consistent: interest is high, mechanistic plausibility exists from cell and animal work, and the human clinical evidence base for TB-500 specifically is thin to nonexistent. If a source tells you TB-500 is "clinically proven" for tendon or ligament repair in humans, that claim isn't backed by the current published literature. The 2024 wound-healing screening study is a good example of the kind of evidence that does exist: it tested TB-500 and its metabolites for wound-healing activity in vitro, using rat pharmacokinetic data to inform dosing in the cell assays, not a human outcome study ^[2].

Is TB-500 legal, and can you buy it as a standalone product?

TB-500 is not an FDA-approved drug. You won't find it in the Drugs@FDA database of approved products ^[6]. That doesn't make simple possession automatically illegal everywhere, but it does mean there's no FDA-reviewed dosing, safety, or manufacturing standard behind it the way there is for an approved medication. Here's the part that trips people up: there is no standalone TB-500 product sold through legitimate compounding channels. TB-500 (and the related peptide BPC-157) fall under FDA's bulk drug substance framework for compounding. FDA maintains lists of bulk substances that compounding pharmacies may use under Section 503A (for state-licensed pharmacies and physicians) and Section 503B (for outsourcing facilities), under 21 CFR 216.23 and 21 CFR 216.24 ^[7][8]. The relevant statute is 21 U.S.C. 353a, which sets conditions for pharmacy compounding ^[9]. FDA's own bulk substances page explains how substances get nominated and evaluated for the 503A list ^[10], and the current nominated-substances list is public ^[11]. In practice, where TB-500 is dispensed through a licensed compounding pharmacy following a provider's order, it's typically combined with BPC-157 in a single blended formulation, not sold as an isolated TB-500 vial. That's the model TB-500 Co works within: a provider-reviewed pathway to a compounded BPC-157/TB-500 blend, dispensed by a licensed pharmacy partner, not a standalone TB-500 SKU sold direct to consumer. If a seller offers you "pure TB-500" with no clinical oversight and no pharmacy behind it, that's a different, much less accountable supply chain. For sourcing questions specifically, see tb 500 for sale.

Is TB-500 banned in sports?

Yes. TB-500 and thymosin beta-4 fall under the World Anti-Doping Agency's prohibited list, and this is one of the more heavily studied areas of the actual TB-500 literature, because anti-doping labs have needed reliable detection methods for over a decade. A 2012 study in the Journal of Chromatography A developed a liquid chromatography-mass spectrometry method specifically to detect TB-500 in equine urine and plasma for doping control ^[12]. A 2013 paper in Analytical and Bioanalytical Chemistry extended doping-control analysis to seven bioactive peptides, including TB-500, in horse plasma ^[13]. A 2014 review in the Journal of Pharmaceutical and Biomedical Analysis covered analytical approaches for detecting emerging therapeutics and non-approved drugs, TB-500 among them, in human doping controls ^[14]. The detection science has kept advancing: a 2016 Journal of Separation Science paper describes a method for screening peptides under 2 kDa (TB-500's active fragment falls in this range) by direct urine injection with ion mobility mass spectrometry ^[15], and a 2016 Drug Testing and Analysis paper worked out solid-phase extraction protocols for small bioactive peptides from human urine specifically to support this kind of screening ^[16]. A 2017 Analytical Biochemistry study even looked at how TB-500 and other doping-relevant peptides adsorb to lab surfaces and collection materials, a practical problem for anyone trying to run a clean assay ^[17]. If you're a competitive athlete under WADA or a national federation's jurisdiction, using TB-500 is a straightforward anti-doping violation risk, independent of what you think about its safety or effectiveness.

How is TB-500 typically dosed in research settings?

There is no FDA-approved or clinically validated human dosing protocol for TB-500. What exists in the public record is animal pharmacokinetic data and community-reported patterns, and those are not the same thing. The 2024 chromatography study that quantified TB-500 and its metabolites did so in rats, generating pharmacokinetic data used to inform the dosing of in vitro wound-healing assays ^[2]. That's useful for understanding how the compound breaks down and how long metabolites persist in a rodent model. It is not a basis for calculating a human dose, and the paper doesn't claim to be. Most of what circulates online as "TB-500 dosing protocols" comes from anecdotal user reports, not peer-reviewed sources. Typical community patterns describe subcutaneous injection, a loading phase of more frequent dosing followed by a maintenance phase, and total dose ranges quoted in milligrams per week. TB-500 Co does not endorse any of these as clinically validated, because none of them are backed by human trial data. If you want the mechanics of reconstitution and injection technique that people commonly describe, see TB-500 how to inject and TB-500 injection sites. For questions about how long a typical research cycle runs and how the product should be stored between doses, see TB-500 cycle length and TB-500 storage and shelf life.

Why is TB-500 usually paired with BPC-157?

In practice, TB-500 is almost never dispensed alone. The common compounded formulation combines it with BPC-157, another research peptide associated with gut and tissue repair signaling in preclinical models. The rationale people give is that TB4-derived peptides and BPC-157 may work through different but complementary mechanisms, one more associated with cell migration and angiogenesis signaling, the other with growth factor and blood vessel-related pathways in animal models. That's a mechanistic hypothesis, not a demonstrated human clinical benefit from combining them. Neither peptide has large human trials establishing efficacy alone, let alone in combination. What is true and verifiable: the compounded blend model is the actual product form available through licensed pharmacy channels. There is no standalone TB-500 vial sold through TB-500 Co; what's dispensed, after provider review, is a compounded BPC-157/TB-500 blend from a licensed pharmacy partner. That's a supply chain reality, not a marketing choice, and it lines up with how both peptides sit on FDA's bulk drug substance lists for compounding under 21 CFR 216.23 and 216.24 ^[7][8].

What are the safety concerns with TB-500?

Because there's no completed human clinical trial program for TB-500, there's no formal FDA-reviewed adverse event profile either. What exists is a mix of animal toxicology-adjacent data, mechanistic reviews, and general caution flagged by orthopaedic and sports medicine reviewers. The 2026 Sports Medicine review on approved versus unapproved peptide therapies for musculoskeletal injuries specifically frames safety and efficacy as a comparison problem: approved peptides went through FDA review, unapproved ones like TB-500 did not, and the evidence bases are not equivalent ^[5]. The 2026 American Journal of Sports Medicine primer aimed at orthopaedic and sports medicine physicians exists largely because clinicians are fielding patient questions about products with no formal safety monitoring, and need a framework for talking about that gap ^[4]. Because TB-500 isn't FDA-approved, there's no standardized manufacturing quality requirement the way there is for an approved drug, which is exactly why sourcing through a licensed compounding pharmacy (rather than an unregulated online seller) matters for product identity and contamination risk, even though it doesn't resolve the underlying lack of human efficacy and long-term safety data.

Does TB-500 have any use in healthy aging research?

There's early-stage interest in thymosin-family peptides within the broader gerontology research field, but this is a mechanisms-and-applications discussion, not an established treatment. A 2026 review in Frontiers in Aging covers therapeutic peptides in gerontology, discussing mechanisms and applications relevant to healthy aging research ^[18]. TB-500 and TB4-related peptides get discussed in this literature because of their proposed roles in cell migration and tissue maintenance signaling, the same mechanisms of interest in the injury-repair context. This is forward-looking research framing, not a clinical recommendation, and the review itself is about mechanisms and applications broadly, not a TB-500-specific human aging trial.

How do labs actually detect and measure TB-500?

This is, ironically, the best-studied part of the entire TB-500 literature. Because it's a prohibited substance in equine and human sport, a decade-plus of analytical chemistry work has gone into figuring out how to find it reliably in blood and urine. Beyond the equine and human doping-detection papers already discussed ^[12][13][14], researchers have built out in vitro metabolic models to understand how TB-500 and similar small peptide hormones break down in the body, which matters for knowing what metabolites to screen for. A 2015 Journal of Peptide Science paper covers in vitro models for metabolic studies of small peptide hormones in sport drug testing generally ^[19]. A 2016 Journal of Proteomics paper compared several in vitro model systems, proteolytic enzymes, human blood serum, liver and kidney microsomes, and liver S9 fraction, for modeling synthetic doping peptide metabolism ^[20]. A 2014 Expert Review of Proteomics paper reviewed the broader challenge of detecting peptidic drugs, candidates, and analogs in sports doping, and a 2015 Journal of Peptide Science paper (noted above) sits alongside it as part of the same detection-science literature ^[21]. None of this analytical work tells you whether TB-500 works for tendon repair in a person. It tells you that if you're a tested athlete, the assumption should be that it's detectable, because labs have spent a decade building assays specifically for that purpose.

TB-500 evidence at a glance

What should someone researching TB-500 actually take away from this?

Treat TB-500 as an actively studied research compound with real analytical and preclinical chemistry behind it, and essentially no human clinical trial base. That's not a dismissal, it's just where the evidence currently sits, and the 2026 orthopaedic and sports medicine reviews say as much when they call for more rigorous human data before treating these peptides as established therapies ^[3][4][5]. If you're an athlete subject to WADA testing, the doping-detection literature alone should settle the question: assume it's detectable and prohibited, full stop ^[12][13][14]. If you're not a tested athlete and you're weighing whether to pursue this through a legitimate channel, understand that no legitimate channel sells standalone TB-500. What you'd get, after a provider reviews your case, is a compounded BPC-157/TB-500 blend dispensed by a licensed pharmacy, made under the bulk drug substance compounding framework FDA has published for exactly this category of product ^[7][8][10]. Anyone offering you isolated TB-500 outside that structure is asking you to trust a supply chain with no pharmacy accountability behind it.

Frequently asked questions

What is TB-500 exactly?

TB-500 is a synthetic peptide built around a short fragment (roughly amino acids 17-23) of thymosin beta-4, a naturally occurring protein involved in cell migration and tissue repair signaling. It's studied mostly in cell culture and animal models, not human trials, and the name is also used loosely online for similar synthetic TB4-fragment products.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is the full 43-amino-acid natural protein. TB-500 is a synthetic peptide based on a small fragment of it. They're related but not identical, and treating study results on one as automatically applying to the other is a common but incorrect assumption in online sourcing.

Can you buy TB-500 as a standalone product?

Not through legitimate compounding channels. TB-500 is typically dispensed only as part of a compounded BPC-157/TB-500 blend through a licensed pharmacy, following provider review, under FDA's bulk drug substance framework for compounding (21 CFR 216.23, 216.24). There's no FDA-approved standalone TB-500 drug product.

Is TB-500 FDA-approved?

No. TB-500 does not appear in the Drugs@FDA database of approved drug products. It's handled under the bulk drug substance compounding framework rather than as an approved medication, meaning there's no FDA-reviewed efficacy or safety data behind it the way there is for approved drugs.

Why is TB-500 always paired with BPC-157?

The common compounded formulation blends both peptides, based on the idea that they act through complementary preclinical mechanisms. This is a supply-chain and formulation reality, not proof of a clinical benefit from combining them; there's no completed human trial demonstrating that the combination outperforms either peptide alone.

Is TB-500 banned by WADA?

Yes. TB-500 and thymosin beta-4 fall under WADA's prohibited list, and anti-doping labs have published multiple validated LC-MS/MS detection methods for it in equine and human doping control since at least 2012. Competitive athletes should assume it's detectable and treat use as a clear anti-doping violation risk.

What dose of TB-500 do studies use?

There is no established human clinical dosing protocol. The main quantitative dosing data available is from a 2024 rat pharmacokinetic study used to inform in vitro wound-healing assay concentrations, not a human dose-finding trial. Community-reported dosing protocols online are anecdotal, not peer-reviewed.

Does TB-500 actually help tendon or ligament repair in humans?

There's no completed human clinical trial establishing this. The evidence is preclinical: cell-based wound-healing screening and animal pharmacokinetic studies. Recent 2026 orthopaedic and sports medicine reviews describe interest in the category while noting the human efficacy evidence for products like TB-500 remains limited.

How is TB-500 detected in drug testing?

Through liquid chromatography-mass spectrometry (LC-MS/MS) methods developed specifically for small peptides. Validated methods exist for equine urine and plasma (2012, 2013) and have been extended into broader human doping-control screening approaches for peptides under 2 kDa, including solid-phase extraction protocols for isolating them from urine.

Is TB-500 legal to possess?

Legal status varies by jurisdiction and isn't the same question as FDA approval. TB-500 isn't FDA-approved and has no standalone legitimate product form; it's compounded into a BPC-157/TB-500 blend under a pharmacy compounding framework. Simple possession laws differ by state and country, so check local rules rather than assuming compounding-framework status settles legality everywhere.

What's the difference between TB-500 research and marketing claims?

The published research is cell-based, animal-based, or analytical chemistry (detection methods, metabolite mapping). Marketing claims about human injury recovery, strength gains, or anti-aging effects generally aren't backed by the peer-reviewed record, which currently has no completed human clinical trials for TB-500 specifically.

Are there safety concerns with unapproved TB-500 products?

Yes, mainly around sourcing and manufacturing quality, since there's no FDA-approved standard for TB-500. A 2026 Sports Medicine review specifically frames the comparison between approved and unapproved peptide therapies as an evidence and safety-monitoring gap, more than an efficacy question.

Sources

1. Drug Testing and Analysis, 2012 (PMID 22962027): Study synthesized and characterized the N-terminal acetylated 17-23 fragment of thymosin beta-4 identified in TB-500 product suspected of doping potential.
2. Journal of Chromatography B, 2024 (PMID 38382158): Quantified TB-500 and its metabolites in vitro and in rats using UHPLC-Q-Exactive Orbitrap MS/MS and screened them for wound-healing activity in vitro.
3. Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, 2026 (PMID 41490200): Reviews applications, challenges, and future directions for therapeutic peptides in orthopaedics.
4. The American Journal of Sports Medicine, 2026 (PMID 41476424): Provides a primer for orthopaedic and sports medicine physicians on injectable peptide therapy.
5. Sports Medicine (Auckland), 2026 (PMID 41966639): Compares safety and efficacy evidence for approved versus unapproved peptide therapies used for musculoskeletal injuries and athletic performance.
6. FDA, Drugs@FDA database: TB-500 does not appear as an FDA-approved drug product in the Drugs@FDA database.
7. 21 CFR 216.23, the 503A Bulks List (eCFR): Establishes the bulk drug substance list applicable to compounding under Section 503A.
8. 21 CFR 216.24, the 503B Bulks List (eCFR): Establishes the bulk drug substance list applicable to compounding by outsourcing facilities under Section 503B.
9. 21 U.S.C. 353a, pharmacy compounding (Cornell Law): Sets statutory conditions under which compounded drug products, including bulk substance compounds, are exempt from certain FDA requirements.
10. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Explains the FDA process for evaluating and nominating bulk drug substances for use in 503A compounding.
11. FDA, bulk drug substances nominated for use in compounding (current list): Current published list of bulk drug substances nominated for compounding use, the framework under which TB-500 blends are handled.
12. Journal of Chromatography A, 2012 (PMID 23084823): Developed a liquid chromatography-mass spectrometry doping control method for TB-500 in equine urine and plasma.
13. Analytical and Bioanalytical Chemistry, 2013 (PMID 23318763): Developed doping control analysis of seven bioactive peptides, including TB-500, in horse plasma by LC-MS.
14. Journal of Pharmaceutical and Biomedical Analysis, 2014 (PMID 24906629): Reviews analytical approaches for detecting emerging therapeutics and non-approved drugs, including TB-500, in human doping controls.
15. Journal of Separation Science, 2016 (PMID 26578461): Describes a method for screening peptides under 2 kDa by direct urine injection with liquid chromatography and ion mobility mass spectrometry.
16. Drug Testing and Analysis, 2016 (PMID 26472487): Developed solid-phase extraction protocols for small bioactive peptides from human urine for doping-control screening.
17. Analytical Biochemistry, 2017 (PMID 28887173): Examined adsorption effects of doping-relevant peptides including TB-500 on laboratory surfaces and materials.
18. Frontiers in Aging, 2026 (PMID 42021992): Reviews mechanisms and applications of therapeutic peptides in gerontology relevant to healthy aging research.
19. Journal of Peptide Science, 2015 (PMID 25469748): Covers in vitro models for metabolic studies of small peptide hormones used in sport drug testing.
20. Journal of Proteomics, 2016 (PMID 27569051): Compared in vitro model systems (proteolytic enzymes, serum, liver/kidney microsomes, liver S9 fraction) for modeling synthetic doping peptide metabolism.
21. Expert Review of Proteomics, 2014 (PMID 25382550): Reviews current status and future directions for detecting peptidic drugs, candidates, and analogs in sports doping.